Navigation Links
Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit
Date:9/30/2009

Drug safety firm BioSoteria, Inc. honored Dr. Hugh H. Tilson with the first PDSS Leadership Award at the 3rd Annual Pacific Drug Safety Summit, which took place last Friday in San Francisco. Dr. Tilson, an internationally acclaimed epidemiologist and outcomes researcher, was the moderator of the event and serves as Chairman of BioSoteria's Board of Advisors.

Emeryville, CA (PRWEB) September 30, 2009 -- BioSoteria, Inc., a drug safety services and training firm, honored Hugh H. Tilson, MD, DrPH, with the first PDSS Leadership Award at the 3rd Annual Pacific Drug Safety Summit, which took place last Friday in San Francisco. Dr. Tilson was the moderator of the event and serves as Chairman of BioSoteria's Board of Advisors.

The award was presented by Sally Van Doren, PharmD, President and Chief Executive Officer of BioSoteria, the conference organizer. In her comments to an audience of nearly 130 drug safety practitioners and providers, Dr. Van Doren remarked, "Hugh's thoughtful, candid and lively participation as keynote speaker and moderator at the three Pacific Drug Safety Summits has contributed to the annual event's unprecedented success."

Upon receiving the award, Dr. Tilson said, "I am especially honored by the words inscribed: 'Living the Vision.' Improving public health is my life's work, and I am pleased to support the vision of PDSS to educate drug safety professionals and create a forum for exchange of best pharmacovigilance practices."

About Hugh H. Tilson, MD, Dr.P.H., FISPE
An internationally acclaimed epidemiologist and outcomes researcher, Dr. Tilson's career in public health and preventive medicine spans forty years. He spent fifteen years in public service, including duties as a U.S. Army Preventive Medicine Officer in Germany; Consultant to the U.S. Office of Economic Opportunity, National Center for Health Services Research, and Veterans Administration; Local Public Health Officer and Human Services Director for Multnomah County in Portland, Oregon; and State Public Health Director for North Carolina.

Dr. Tilson then joined The Wellcome Foundation (now GlaxoSmithKline), where he introduced many epidemiologic principles and innovations to the private sector. Upon his retirement in 1996, he joined the full-time clinical faculty of University of North Carolina (UNC) School of Public Health in Chapel Hill. He is currently Adjunct Professor at UNC and at Duke University.

Besides serving as chairman of the BioSoteria Board of Advisors, Dr. Tilson is a member of the Board of Public Responsibility in Medicine & Research (PRIM&R) and the new national Public Health Accreditation Board (PHAB). He was a member of the Council for International Organisations for the Medical Sciences (CIOMS) Working Groups on Drug Safety from 1990 to 2001, and an advisor to the recent CIOMS VI and to the World Health Organization (WHO) Collaborating Centres. Dr. Tilson chaired the National Steering Committee for the Centers for Education and Research on Therapeutics (CERTs) program for the Agency for Healthcare Research and Quality (AHRQ) from 1999 to 2009. He served on the Institute of Medicine (IOM) report 'The Future of the Public's Health,' and most recently advised on the landmark 'Future of Drug Safety' IOM study. He is a co-editor of the first textbook of pharmacoepidemiology, now in its fourth edition as 'Pharmacoepidemiology and Therapeutic Risk Management.'

About the Pacific Drug Safety Summit (PDSS)
With a solid one-day agenda of contemporary drug safety and risk management topics, PDSS is a scientific conference held annually in the San Francisco Bay Area. What began as a small regional event in 2007 now attracts speakers, attendees, and sponsors across the U.S. and around the globe. For more information on PDSS09, please visit www.pacificdrugsafetysummit.com. PDSS10 will be held on September 24, 2010, in San Francisco, CA. Details on the agenda, logistics, and sponsorship opportunities will be announced as they become available.

About BioSoteria, Inc.
BioSoteria provides innovative drug safety services and education to the biopharmaceutical industry and healthcare community. The company offers a wide range of pharmacovigilance services throughout the product lifecycle, including premarketing clinical safety surveillance, postmarketing safety monitoring, and risk management programs. BioSoteria-sponsored educational programs include the annual Pacific Drug Safety Summit and eLadder(TM) Safety, the first comprehensive drug safety training curriculum delivered in a true eLearning environment. To learn more about BioSoteria, visit the company's website at www.biosoteria.com or call toll-free at 1-866-660-5553.


###

Read the full story at http://www.prweb.com/releases/pdss/leadershipaward/prweb2965934.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit 
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):